Joseph A. Tyndall net worth and biography

Joseph Tyndall Biography and Net Worth

Director of AxoGen

Dr. Tyndall has served as a member of our Board of Directors since December 2022. Since July 1, 2021, Dr. Tyndall has been a professor, Executive Vice President for Health Affairs and Dean at the Morehouse School of Medicine. Prior to Morehouse School of Medicine, Dr. Tyndall served as a professor and chair of the Department of Emergency Medicine at the University of Florida (UF) College of Medicine from 2008 until his departure from UF in 2021. During his tenure at UF, he was appointed interim dean of the College of Medicine from August 2018 to January 2021 and was subsequently appointed to the position of associate vice president for strategic and academic affairs for UF Health in Gainesville, Florida, before his recruitment to Morehouse School of Medicine. He served on the Board of Directors of UF Health Shands Hospital at the University of Florida from 2010 through 2021 and was chair of the Board of Trustees for the UF Health Proton Therapy Institute during his tenure as interim dean. He served on the Board of Directors of the Florida College of Emergency Physicians from 2011 through 2021, serving as the society’s president from 2018 to 2019. He is currently a member of the Board of Directors of Grady Health System in Atlanta, Georgia. Also, he is a trustee and immediate past president of the Society for Academic Emergency Medicine Foundation, which is emergency medicine’s national foundation supporting education and research in emergency care. Dr. Tyndall is a graduate of the University of Maryland School of Medicine and the emergency medicine residency program at the University of Maryland Medical System, where he served as Chief Resident. He received his master’s degree in Health Services Management and Health Policy from Columbia University and a bachelor’s degree in Chemistry from The George Washington University. He is an elected member of the Alpha Omega Alpha Honor Society and the Gold Humanism Honor Society. He is the current president of the Society for Academic Emergency Medicine Foundation and was also recently elected to serve a two-year term on the administrative board of the Council of Deans of the Association of American Medical College. He has published and lectured extensively nationally and internationally in emergency medicine and has active research interests in acute brain injury. He is an editor of the 10th edition of a leading textbook in emergency medicine, Rosen’s Emergency Medicine; Concepts and Clinical Practice. Dr. Tyndall’s qualifications to serve on our Board of Directors include his extensive experience with the field of emergency medicine, knowledge of the healthcare industry and medical systems, considerable leadership experience, and deep engagement with topics within health services research.

What is Joseph A. Tyndall's net worth?: The estimated net worth of Joseph A. Tyndall is at least $504.08 thousand as of May 22nd, 2025. Tyndall owns 15,345 shares of AxoGen stock worth more than $504,083 as of December 4th. This net worth evaluation does not reflect any other assets that Tyndall may own. Learn More about Joseph A. Tyndall's net worth.
How do I contact Joseph A. Tyndall?: The corporate mailing address for Tyndall and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at [email protected]. Learn More on Joseph A. Tyndall's contact information.
Has Joseph A. Tyndall been buying or selling shares of AxoGen?: Joseph A. Tyndall has not been actively trading shares of AxoGen within the last three months. Most recently, Joseph A. Tyndall sold 20,062 shares of the business's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $11.20, for a transaction totalling $224,694.40. Following the completion of the sale, the director now directly owns 15,345 shares of the company's stock, valued at $171,864. Learn More on Joseph A. Tyndall's trading history.
Who are AxoGen's active insiders?: AxoGen's insider roster includes P Burke (Director), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Joseph Tyndall (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.
Are insiders buying or selling shares of AxoGen?: In the last twelve months, insiders at the medical equipment provider sold shares 16 times. They sold a total of 173,773 shares worth more than $3,429,182.24. The most recent insider tranaction occured on November, 11th when Director William P Mr. Burke sold 3,591 shares worth more than $86,255.82. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.
Information on this page was last updated on 11/11/2025.

Joseph A. Tyndall Insider Trading History at AxoGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/22/2025	Sell	20,062	$11.20	$224,694.40	15,345

Joseph A. Tyndall Buying and Selling Activity at AxoGen

AxoGen Company Overview

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Today's Range

Now: $32.85

$30.24

$34.24

50 Day Range

MA: $21.72

$15.59

$32.85

2 Week Range

Now: $32.85

$9.22

$34.24

Volume

3,164,205 shs

Average Volume

740,537 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06